Verona Pharma's ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes PDE3 and PDE4, targeting both bronchodilation and inflammation. Positive Phase 3 results from the ENHANCE ...

LONDON and RALEIGH, N.C., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), today announces positive results of its Phase 3 ENHANCE-1 trial ...

David Zaccardelli, Pharm. D., Verona Pharma's President and Chief Executive Officer, said:“We are very pleased by the successful outcome of our ENHANCE-2 study and remain committed to bringing ...

Chronic obstructive pulmonary disease phase 3 study shows statistically significant improvements in lung function Chronic obstructive pulmonary disease phase 3 study shows statistically significant ...

LONDON and RALEIGH, N.C., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces ...

LONDON and RALEIGH, N.C., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces ...

LONDON and RALEIGH, N.C. and SHANGHAI, China, June 10, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) and Nuance Pharma Limited (“Nuance Pharma”), today announce that the ...

LONDON and RALEIGH, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces additional exacerbation* subgroup analyses from the Phase 3 ...

Conference call today at 8:30 a.m. EST / 1:30 p.m. GMT LONDON and RALEIGH, N.C., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the“Company”), today announces ...

LONDON and RALEIGH, N.C., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), today announces its top-line Phase 3 ENHANCE-2 (“Ensifentrine as a ...